Two studies reject the scientific dogma associating ageing with the loss of stem cell circadian rhythm Blog Post

Two studies published in Cell by scientists from the Institute for Research in Biomedicine (IRB Barcelona) at the Barcelona Science Park, the Pompeu Fabra University (UPF) and the University of California, Irvine (UCI) reject the scientific dogma associating ageing with the loss of stem cell circadian rhythm. Their results reveal that stem cell functions continue to be governed by day and night cycles (circadian rhythms) during ageing, but their rhythms become devoted to tissue repair and not to the maintenance of tissue tone.

 

SOM Biotech opens a €10 million Series A funding round Blog Post

The biopharmaceutical company SOM Biotech –and specialised in repositioning drugs to treat rare nervous system diseases– has just opened a Series A round with the goal of raising €10 million, targeted to top US and European biotech venture capital. Since it was founded at the Barcelona Science Park in 2009, SOM Biotech has raised more than €5.3 million from public and private capital, and has placed 8 patents for new medical indications and formulations.

 

Seminar on CDTI Instruments to fund R&D&i projects and startups Blog Post

On July 25 the Barcelona Science Park – in collaboration with the Centre for the Development of Industrial Technology (CDTI), Biocat and the Bosch i Gimpera Foundation (FBG)- organizes a seminar to introduce the different instruments that the CDTI has to fund R&D&i projects and to present the initiatives of its programs for this 2017 in the healthcare sector.

 

The 16th edition of the ‘Spend the summer at the Park!’ program has started Blog Post

The welcome ceremony to participants of the Spend the summer at the Park! program as held today, Monday, July 10. The aim of this initiative –organised annually by the Barcelona Science Park (PCB)– is to bring research closer to students of any university in the world through their participation in projects currently being carried out in research groups, research centres and companies based at the PCB.

 

Present your innovative project at the Asebio Investor Day! Blog Post

The Spanish Bioindustry Association (ASEBIO) and the Spanish Biotech Platform organize the Asebio Investor Day, in collaboration with PCB and Biocat and with the support of ICEX-Invest in Spain. The event will be held on 26 and 27 September at PCB and it is composed of two parts: An investor forum, with leading investors and pharmaceutical companies from around the world on 27 September, and a seminar given by Johnson & Johnson Innovation JLABS on 26 Setember. 

 

The Drosophila fly brings to light the role of morphogens in limb growth Blog Post

Researchers working in the Development and Growth Control Lab at IRB Barcelona located at the Barcelona Science Park reveal that the Dpp gene (BMP in humans) plays a double role in the structural organisation and growth of the wings of the fruit fly Drosophila melanogaster. Published in the journal eLife, this study paves the way to studying vertebrate development and congenital defects in humans.

 

The Institute for Bioengineering of Catalonia joins BIST Foundation Blog Post

The Board of the Barcelona Institute of Science and Technology (BIST) has approved the incorporation of the Institute for Bioengineering of Catalonia (IBEC) –based at the Barcelona Science Park– as a new member. At its annual meeting held today in Barcelona, the Board has also appointed Gabriel M. Silberman as a new BIST general director, replacing Miquel A. Pericàs, director of the Institute of Chemical Research of Catalonia (ICIQ).

 

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain Blog Post

Esteve at the Barcelona Science Park co-leads the NGN-PET consortium, that unites the expertise and knowledge of industry partners from the European Federation of Pharmaceutical Industries and Associations (EFPIA), small and medium-sized enterprises (SMEs) and academia for the development of novel, more efficacious treatments for chronic pain of neuropathic origin. NGN-PET is a project launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry.